183 related articles for article (PubMed ID: 35128939)
1. Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study.
Usmani OS; Baldi S; Warren S; Panni I; Girardello L; Rony F; Taylor G; DeBacker W; Georges G
J Aerosol Med Pulm Drug Deliv; 2022 Aug; 35(4):179-185. PubMed ID: 35128939
[No Abstract] [Full Text] [Related]
2. Predicting Lung Deposition of Extrafine Inhaled Corticosteroid-Containing Fixed Combinations in Patients with Chronic Obstructive Pulmonary Disease Using Functional Respiratory Imaging: An
Usmani OS; Mignot B; Kendall I; Maria R; Cocconi D; Georges G; Scichilone N
J Aerosol Med Pulm Drug Deliv; 2021 Jun; 34(3):204-211. PubMed ID: 33052749
[No Abstract] [Full Text] [Related]
3. Ethnic Sensitivity Study of the Extrafine, Single-Inhaler, Triple Therapy Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide Pressurized Metered Dose Inhaler in Japanese and Caucasian Healthy Individuals: A Randomized, Double-Blind, Single-Dose Crossover Study.
Cella M; Täubel J; Delestre-Levai I; Tulard A; Vele A; Georges G
Clin Ther; 2021 Nov; 43(11):1934-1947.e4. PubMed ID: 34600734
[TBL] [Abstract][Full Text] [Related]
4. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma.
Kuna P; Jerzynska J; Martini M; Vele A; Barneschi I; Mariotti F; Georges G; Ciurlia G
Pharmacol Res Perspect; 2022 Aug; 10(4):e980. PubMed ID: 35733414
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects.
Hu C; Miao J; Shu S; Wang Y; Zhu X; Luo Z
Eur J Pharm Sci; 2020 Mar; 144():105198. PubMed ID: 31862312
[TBL] [Abstract][Full Text] [Related]
7. Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations.
Usmani OS; Scichilone N; Mignot B; Belmans D; Van Holsbeke C; De Backer J; De Maria R; Cuoghi E; Topole E; Georges G
Int J Chron Obstruct Pulmon Dis; 2020; 15():2433-2440. PubMed ID: 33116458
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial.
Beeh KM; Kuna P; Corradi M; Viaud I; Guasconi A; Georges G
Int J Chron Obstruct Pulmon Dis; 2021; 16():79-89. PubMed ID: 33488071
[TBL] [Abstract][Full Text] [Related]
9. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
[TBL] [Abstract][Full Text] [Related]
10. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients.
De Backer W; Devolder A; Poli G; Acerbi D; Monno R; Herpich C; Sommerer K; Meyer T; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):137-48. PubMed ID: 20109122
[TBL] [Abstract][Full Text] [Related]
11. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers.
Luo Z; Lucci G; Santoro L; Topole E; Mariotti F
Pulm Pharmacol Ther; 2022 Jun; 73-74():102129. PubMed ID: 35525480
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England.
Orlovic M; Magni T; Lukyanov V; Guerra I; Madoni A
Respir Med; 2022 Sep; 201():106934. PubMed ID: 35872377
[TBL] [Abstract][Full Text] [Related]
15. A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993.
Mariotti F; Ciurlia G; Spaccapelo L; Muraro A; Acerbi D
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):269-279. PubMed ID: 27209586
[TBL] [Abstract][Full Text] [Related]
16. Comparison of extrafine beclomethasone dipropionate/formoterol fumarate dry powder inhaler and pressurized metered-dose inhaler in Chinese patients with asthma: the FORTUNE study.
Zheng J; Zhang J; Fu X; Lin C; Zhang X; Mei X; Corradi M; Cappellini G; Calabro E; Zhu C; Topole E
J Asthma; 2024 Apr; 61(4):360-367. PubMed ID: 37878325
[TBL] [Abstract][Full Text] [Related]
17. Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study.
Rogliani P; Ora J; Girolami A; Rossi I; de Guido I; Facciolo F; Cazzola M; Calzetta L
Pulm Pharmacol Ther; 2021 Aug; 69():102050. PubMed ID: 34129945
[TBL] [Abstract][Full Text] [Related]
18. Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER.
Singh D; Virchow JC; Canonica GW; Vele A; Kots M; Georges G; Papi A
Respir Res; 2020 Oct; 21(1):285. PubMed ID: 33121501
[TBL] [Abstract][Full Text] [Related]
19. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.
Kanniess F; Scuri M; Vezzoli S; Francisco C; Petruzzelli S
Pulm Pharmacol Ther; 2015 Feb; 30():121-7. PubMed ID: 25088067
[TBL] [Abstract][Full Text] [Related]
20. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]